OMB APPROVAL
----------------------------
OMB Number: 3235-0145
Expires: December 31, 2005
Estimated average burden
hours per response. . . . 15
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
SCHEDULE 13D
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(AMENDMENT NO. ___ )*
XCYTE THERAPIES, INC.
(Name of Issuer)
COMMON STOCK
(Title of Class of Securities)
98389F309
(CUSIP Number)
MARK MCDONNELL
ARCH VENTURE FUND V, L.P.
8725 W. HIGGINS ROAD SUITE 290
CHICAGO, IL 60631
(Name, Address and Telephone Number of Person Authorized to Receive Notices and
Communications)
NOVEMBER 3, 2004
(Date of Event which Requires Filing of this Statement)
If the filing person has previously filed a statement on Schedule 13G to report
the acquisition that is the subject of this Schedule 13D, and is filing this
schedule because of Sections 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check
the following box. [ ]
NOTE: Schedules filed in paper format shall include a signed original and five
copies of the schedule, including all exhibits. See Section 240.13d-7 for other
parties to whom copies are to be sent.
*The remainder of this cover page shall be filled out for a reporting person's
initial filing on this form with respect to the subject class of securities, and
for any subsequent amendment containing information which would alter
disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not be deemed
to be "filed" for the purpose of Section 18 of the Securities Exchange Act of
1934 ("Act") or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the Act (however, see the
Notes).
--------------------------------------------------------------------------------
CUSIP NO. 98389F309 13D PAGE 2 OF 29 PAGES
--------------------------------------------------------------------------------
--------------------------------------------------------------------------------
1 NAMES OF REPORTING PERSONS.
ARCH Venture Fund V, L.P.
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY).
[-------------]
--------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a) [ ]
(b) [ ]
--------------------------------------------------------------------------------
3 SEC USE ONLY
--------------------------------------------------------------------------------
4 SOURCE OF FUNDS
WC
--------------------------------------------------------------------------------
5 CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS
2(d) or 2(e) [ ]
--------------------------------------------------------------------------------
6 CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
--------------------------------------------------------------------------------
7 SOLE VOTING POWER
NUMBER OF 0
SHARES --------------------------------------------------------------
BENEFICIALLY 8 SHARED VOTING POWER
OWNED BY 2,905,331
EACH REPORTING --------------------------------------------------------------
PERSON 9 SOLE DISPOSITIVE POWER
WITH 0
--------------------------------------------------------------
10 SHARED DISPOSITIVE POWER
2,905,331
--------------------------------------------------------------------------------
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
2,905,331
--------------------------------------------------------------------------------
12 CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES [ ]
--------------------------------------------------------------------------------
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
18.5%
--------------------------------------------------------------------------------
14 TYPE OF REPORTING PERSON
PN
--------------------------------------------------------------------------------
--------------------------------------------------------------------------------
CUSIP NO. 98389F309 13D PAGE 3 OF 29 PAGES
--------------------------------------------------------------------------------
--------------------------------------------------------------------------------
1 NAMES OF REPORTING PERSONS.
ARCH Venture Fund III, L.P.
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY).
--------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a) [ ]
(b) [ ]
--------------------------------------------------------------------------------
3 SEC USE ONLY
--------------------------------------------------------------------------------
4 SOURCE OF FUNDS
WC
--------------------------------------------------------------------------------
5 CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS
2(d) or 2(e) [ ]
--------------------------------------------------------------------------------
6 CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
--------------------------------------------------------------------------------
7 SOLE VOTING POWER
NUMBER OF 0
SHARES --------------------------------------------------------------
BENEFICIALLY 8 SHARED VOTING POWER
OWNED BY 2,905,331
EACH REPORTING --------------------------------------------------------------
PERSON 9 SOLE DISPOSITIVE POWER
WITH 0
--------------------------------------------------------------
10 SHARED DISPOSITIVE POWER
2,905,331
--------------------------------------------------------------------------------
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
2,905,331
--------------------------------------------------------------------------------
12 CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES [ ]
--------------------------------------------------------------------------------
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
18.5%
--------------------------------------------------------------------------------
14 TYPE OF REPORTING PERSON
PN
--------------------------------------------------------------------------------
--------------------------------------------------------------------------------
CUSIP NO. 98389F309 13D PAGE 4 OF 29 PAGES
--------------------------------------------------------------------------------
--------------------------------------------------------------------------------
1 NAMES OF REPORTING PERSONS.
ARCH Venture Fund II, L.P.
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY).
--------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a) [ ]
(b) [ ]
--------------------------------------------------------------------------------
3 SEC USE ONLY
--------------------------------------------------------------------------------
4 SOURCE OF FUNDS
WC
--------------------------------------------------------------------------------
5 CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS
2(d) or 2(e) [ ]
--------------------------------------------------------------------------------
6 CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
--------------------------------------------------------------------------------
7 SOLE VOTING POWER
NUMBER OF 0
SHARES --------------------------------------------------------------
BENEFICIALLY 8 SHARED VOTING POWER
OWNED BY 2,905,331
EACH REPORTING --------------------------------------------------------------
PERSON 9 SOLE DISPOSITIVE POWER
WITH 0
--------------------------------------------------------------
10 SHARED DISPOSITIVE POWER
2,905,331
--------------------------------------------------------------------------------
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
2,905,331
--------------------------------------------------------------------------------
12 CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES [ ]
--------------------------------------------------------------------------------
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
18.5%
--------------------------------------------------------------------------------
14 TYPE OF REPORTING PERSON
PN
--------------------------------------------------------------------------------
--------------------------------------------------------------------------------
CUSIP NO. 98389F309 13D PAGE 5 OF 29 PAGES
--------------------------------------------------------------------------------
--------------------------------------------------------------------------------
1 NAMES OF REPORTING PERSONS.
ARCH V Entrepreneurs Fund, L.P.
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY).
--------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a) [ ]
(b) [ ]
--------------------------------------------------------------------------------
3 SEC USE ONLY
--------------------------------------------------------------------------------
4 SOURCE OF FUNDS
WC
--------------------------------------------------------------------------------
5 CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS
2(d) or 2(e) [ ]
--------------------------------------------------------------------------------
6 CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
--------------------------------------------------------------------------------
7 SOLE VOTING POWER
NUMBER OF 0
SHARES --------------------------------------------------------------
BENEFICIALLY 8 SHARED VOTING POWER
OWNED BY 2,905,331
EACH REPORTING --------------------------------------------------------------
PERSON 9 SOLE DISPOSITIVE POWER
WITH 0
--------------------------------------------------------------
10 SHARED DISPOSITIVE POWER
2,905,331
--------------------------------------------------------------------------------
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
2,905,331
--------------------------------------------------------------------------------
12 CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES [ ]
--------------------------------------------------------------------------------
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
18.5%
--------------------------------------------------------------------------------
14 TYPE OF REPORTING PERSON
PN
--------------------------------------------------------------------------------
--------------------------------------------------------------------------------
CUSIP NO. 98389F309 13D PAGE 6 OF 29 PAGES
--------------------------------------------------------------------------------
--------------------------------------------------------------------------------
1 NAMES OF REPORTING PERSONS.
Healthcare Focus Fund, L.P.
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY).
--------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a) [ ]
(b) [ ]
--------------------------------------------------------------------------------
3 SEC USE ONLY
--------------------------------------------------------------------------------
4 SOURCE OF FUNDS
WC
--------------------------------------------------------------------------------
5 CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS
2(d) or 2(e) [ ]
--------------------------------------------------------------------------------
6 CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
--------------------------------------------------------------------------------
7 SOLE VOTING POWER
NUMBER OF 0
SHARES --------------------------------------------------------------
BENEFICIALLY 8 SHARED VOTING POWER
OWNED BY 2,905,331
EACH REPORTING --------------------------------------------------------------
PERSON 9 SOLE DISPOSITIVE POWER
WITH 0
--------------------------------------------------------------
10 SHARED DISPOSITIVE POWER
2,905,331
--------------------------------------------------------------------------------
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
2,905,331
--------------------------------------------------------------------------------
12 CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES [ ]
--------------------------------------------------------------------------------
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
18.5%
--------------------------------------------------------------------------------
14 TYPE OF REPORTING PERSON
PN
--------------------------------------------------------------------------------
--------------------------------------------------------------------------------
CUSIP NO. 98389F309 13D PAGE 7 OF 29 PAGES
--------------------------------------------------------------------------------
--------------------------------------------------------------------------------
1 NAMES OF REPORTING PERSONS.
ARCH Venture Partners V, L.P.
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY).
--------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a) [ ]
(b) [ ]
--------------------------------------------------------------------------------
3 SEC USE ONLY
--------------------------------------------------------------------------------
4 SOURCE OF FUNDS
WC
--------------------------------------------------------------------------------
5 CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS
2(d) or 2(e) [ ]
--------------------------------------------------------------------------------
6 CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
--------------------------------------------------------------------------------
7 SOLE VOTING POWER
NUMBER OF 0
SHARES --------------------------------------------------------------
BENEFICIALLY 8 SHARED VOTING POWER
OWNED BY 2,905,331
EACH REPORTING --------------------------------------------------------------
PERSON 9 SOLE DISPOSITIVE POWER
WITH 0
--------------------------------------------------------------
10 SHARED DISPOSITIVE POWER
2,905,331
--------------------------------------------------------------------------------
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
2,905,331
--------------------------------------------------------------------------------
12 CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES [ ]
--------------------------------------------------------------------------------
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
18.5%
--------------------------------------------------------------------------------
14 TYPE OF REPORTING PERSON
PN
--------------------------------------------------------------------------------
--------------------------------------------------------------------------------
CUSIP NO. 98389F309 13D PAGE 8 OF 29 PAGES
--------------------------------------------------------------------------------
--------------------------------------------------------------------------------
1 NAMES OF REPORTING PERSONS.
ARCH Venture Partners V, LLC
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY).
--------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a) [ ]
(b) [ ]
--------------------------------------------------------------------------------
3 SEC USE ONLY
--------------------------------------------------------------------------------
4 SOURCE OF FUNDS
WC
--------------------------------------------------------------------------------
5 CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS
2(d) or 2(e) [ ]
--------------------------------------------------------------------------------
6 CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
--------------------------------------------------------------------------------
7 SOLE VOTING POWER
NUMBER OF 0
SHARES --------------------------------------------------------------
BENEFICIALLY 8 SHARED VOTING POWER
OWNED BY 2,905,331
EACH REPORTING --------------------------------------------------------------
PERSON 9 SOLE DISPOSITIVE POWER
WITH 0
--------------------------------------------------------------
10 SHARED DISPOSITIVE POWER
2,905,331
--------------------------------------------------------------------------------
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
2,905,331
--------------------------------------------------------------------------------
12 CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES [ ]
--------------------------------------------------------------------------------
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
18.5%
--------------------------------------------------------------------------------
14 TYPE OF REPORTING PERSON
OO Limited Liability Company
--------------------------------------------------------------------------------
--------------------------------------------------------------------------------
CUSIP NO. 98389F309 13D PAGE 9 OF 29 PAGES
--------------------------------------------------------------------------------
--------------------------------------------------------------------------------
1 NAMES OF REPORTING PERSONS.
ARCH Venture Partners, LLC
--------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a) [ ]
(b) [ ]
--------------------------------------------------------------------------------
3 SEC USE ONLY
--------------------------------------------------------------------------------
4 SOURCE OF FUNDS
WC
--------------------------------------------------------------------------------
5 CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS
2(d) or 2(e) [ ]
--------------------------------------------------------------------------------
6 CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
--------------------------------------------------------------------------------
7 SOLE VOTING POWER
NUMBER OF 0
SHARES --------------------------------------------------------------
BENEFICIALLY 8 SHARED VOTING POWER
OWNED BY 2,905,331
EACH REPORTING --------------------------------------------------------------
PERSON 9 SOLE DISPOSITIVE POWER
WITH 0
--------------------------------------------------------------
10 SHARED DISPOSITIVE POWER
2,905,331
--------------------------------------------------------------------------------
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
2,905,331
--------------------------------------------------------------------------------
12 CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES [ ]
--------------------------------------------------------------------------------
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
18.5%
--------------------------------------------------------------------------------
14 TYPE OF REPORTING PERSON
OO Limited Liability Company
--------------------------------------------------------------------------------
--------------------------------------------------------------------------------
CUSIP NO. 98389F309 13D PAGE 10 OF 29 PAGES
--------------------------------------------------------------------------------
--------------------------------------------------------------------------------
1 NAMES OF REPORTING PERSONS.
ARCH Management Partners II, L.P.
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY).
--------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a) [ ]
(b) [ ]
--------------------------------------------------------------------------------
3 SEC USE ONLY
--------------------------------------------------------------------------------
4 SOURCE OF FUNDS
WC
--------------------------------------------------------------------------------
5 CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS
2(d) or 2(e) [ ]
--------------------------------------------------------------------------------
6 CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
--------------------------------------------------------------------------------
7 SOLE VOTING POWER
NUMBER OF 0
SHARES --------------------------------------------------------------
BENEFICIALLY 8 SHARED VOTING POWER
OWNED BY 2,905,331
EACH REPORTING --------------------------------------------------------------
PERSON 9 SOLE DISPOSITIVE POWER
WITH 0
--------------------------------------------------------------
10 SHARED DISPOSITIVE POWER
2,905,331
--------------------------------------------------------------------------------
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
2,905,331
--------------------------------------------------------------------------------
12 CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES [ ]
--------------------------------------------------------------------------------
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
18.5%
--------------------------------------------------------------------------------
14 TYPE OF REPORTING PERSON
PN
--------------------------------------------------------------------------------
--------------------------------------------------------------------------------
CUSIP NO. 98389F309 13D PAGE 11 OF 29 PAGES
--------------------------------------------------------------------------------
--------------------------------------------------------------------------------
1 NAMES OF REPORTING PERSONS.
ARCH Venture Partners, L.P.
--------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a) [ ]
(b) [ ]
--------------------------------------------------------------------------------
3 SEC USE ONLY
--------------------------------------------------------------------------------
4 SOURCE OF FUNDS
WC
--------------------------------------------------------------------------------
5 CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS
2(d) or 2(e) [ ]
--------------------------------------------------------------------------------
6 CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
--------------------------------------------------------------------------------
7 SOLE VOTING POWER
NUMBER OF 0
SHARES --------------------------------------------------------------
BENEFICIALLY 8 SHARED VOTING POWER
OWNED BY 2,905,331
EACH REPORTING --------------------------------------------------------------
PERSON 9 SOLE DISPOSITIVE POWER
WITH 0
--------------------------------------------------------------
10 SHARED DISPOSITIVE POWER
2,905,331
--------------------------------------------------------------------------------
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
2,905,331
--------------------------------------------------------------------------------
12 CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES [ ]
--------------------------------------------------------------------------------
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
18.5%
--------------------------------------------------------------------------------
14 TYPE OF REPORTING PERSON
PN
--------------------------------------------------------------------------------
--------------------------------------------------------------------------------
CUSIP NO. 98389F309 13D PAGE 12 OF 29 PAGES
--------------------------------------------------------------------------------
--------------------------------------------------------------------------------
1 NAMES OF REPORTING PERSONS.
ARCH Venture Corporation
--------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a) [ ]
(b) [ ]
--------------------------------------------------------------------------------
3 SEC USE ONLY
--------------------------------------------------------------------------------
4 SOURCE OF FUNDS
WC
--------------------------------------------------------------------------------
5 CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS
2(d) or 2(e) [ ]
--------------------------------------------------------------------------------
6 CITIZENSHIP OR PLACE OF ORGANIZATION
Illinois
--------------------------------------------------------------------------------
7 SOLE VOTING POWER
NUMBER OF 0
SHARES --------------------------------------------------------------
BENEFICIALLY 8 SHARED VOTING POWER
OWNED BY 2,905,331
EACH REPORTING --------------------------------------------------------------
PERSON 9 SOLE DISPOSITIVE POWER
WITH 0
--------------------------------------------------------------
10 SHARED DISPOSITIVE POWER
2,905,331
--------------------------------------------------------------------------------
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
2,905,331
--------------------------------------------------------------------------------
12 CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES [ ]
--------------------------------------------------------------------------------
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
18.5%
--------------------------------------------------------------------------------
14 TYPE OF REPORTING PERSON
CO
--------------------------------------------------------------------------------
--------------------------------------------------------------------------------
CUSIP NO. 98389F309 13D PAGE 13 OF 29 PAGES
--------------------------------------------------------------------------------
--------------------------------------------------------------------------------
1 NAMES OF REPORTING PERSONS.
Steven Lazarus
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY).
--------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a) [ ]
(b) [ ]
--------------------------------------------------------------------------------
3 SEC USE ONLY
--------------------------------------------------------------------------------
4 SOURCE OF FUNDS
WC
--------------------------------------------------------------------------------
5 CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS
2(d) or 2(e) [ ]
--------------------------------------------------------------------------------
6 CITIZENSHIP OR PLACE OF ORGANIZATION
United States
--------------------------------------------------------------------------------
7 SOLE VOTING POWER
NUMBER OF 0
SHARES --------------------------------------------------------------
BENEFICIALLY 8 SHARED VOTING POWER
OWNED BY 2,905,331
EACH REPORTING --------------------------------------------------------------
PERSON 9 SOLE DISPOSITIVE POWER
WITH 0
--------------------------------------------------------------
10 SHARED DISPOSITIVE POWER
2,905,331
--------------------------------------------------------------------------------
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
2,905,331
--------------------------------------------------------------------------------
12 CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES [ ]
--------------------------------------------------------------------------------
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
18.5%
--------------------------------------------------------------------------------
14 TYPE OF REPORTING PERSON
IN
--------------------------------------------------------------------------------
--------------------------------------------------------------------------------
CUSIP NO. 98389F309 13D PAGE 14 OF 29 PAGES
--------------------------------------------------------------------------------
--------------------------------------------------------------------------------
1 NAMES OF REPORTING PERSONS.
Keith Crandell
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY).
--------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a) [ ]
(b) [ ]
--------------------------------------------------------------------------------
3 SEC USE ONLY
--------------------------------------------------------------------------------
4 SOURCE OF FUNDS
WC
--------------------------------------------------------------------------------
5 CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS
2(d) or 2(e) [ ]
--------------------------------------------------------------------------------
6 CITIZENSHIP OR PLACE OF ORGANIZATION
United States
--------------------------------------------------------------------------------
7 SOLE VOTING POWER
NUMBER OF 0
SHARES --------------------------------------------------------------
BENEFICIALLY 8 SHARED VOTING POWER
OWNED BY 2,905,331
EACH REPORTING --------------------------------------------------------------
PERSON 9 SOLE DISPOSITIVE POWER
WITH 0
--------------------------------------------------------------
10 SHARED DISPOSITIVE POWER
2,905,331
--------------------------------------------------------------------------------
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
2,905,331
--------------------------------------------------------------------------------
12 CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES [ ]
--------------------------------------------------------------------------------
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
18.5%
--------------------------------------------------------------------------------
14 TYPE OF REPORTING PERSON
IN
--------------------------------------------------------------------------------
--------------------------------------------------------------------------------
CUSIP NO. 98389F309 13D PAGE 15 OF 29 PAGES
--------------------------------------------------------------------------------
--------------------------------------------------------------------------------
1 NAMES OF REPORTING PERSONS.
Robert Nelsen
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY).
--------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a) [ ]
(b) [ ]
--------------------------------------------------------------------------------
3 SEC USE ONLY
--------------------------------------------------------------------------------
4 SOURCE OF FUNDS
WC
--------------------------------------------------------------------------------
5 CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS
2(d) or 2(e) [ ]
--------------------------------------------------------------------------------
6 CITIZENSHIP OR PLACE OF ORGANIZATION
United States
--------------------------------------------------------------------------------
7 SOLE VOTING POWER
NUMBER OF 0
SHARES --------------------------------------------------------------
BENEFICIALLY 8 SHARED VOTING POWER
OWNED BY 2,905,331
EACH REPORTING --------------------------------------------------------------
PERSON 9 SOLE DISPOSITIVE POWER
WITH 0
--------------------------------------------------------------
10 SHARED DISPOSITIVE POWER
2,905,331
--------------------------------------------------------------------------------
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
2,905,331
--------------------------------------------------------------------------------
12 CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES [ ]
--------------------------------------------------------------------------------
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
18.5%
--------------------------------------------------------------------------------
14 TYPE OF REPORTING PERSON
IN
--------------------------------------------------------------------------------
--------------------------------------------------------------------------------
CUSIP NO. 98389F309 13D PAGE 16 OF 29 PAGES
--------------------------------------------------------------------------------
--------------------------------------------------------------------------------
1 NAMES OF REPORTING PERSONS.
Clinton Bybee
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY).
--------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a) [ ]
(b) [ ]
--------------------------------------------------------------------------------
3 SEC USE ONLY
--------------------------------------------------------------------------------
4 SOURCE OF FUNDS
WC
--------------------------------------------------------------------------------
5 CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS
2(d) or 2(e) [ ]
--------------------------------------------------------------------------------
6 CITIZENSHIP OR PLACE OF ORGANIZATION
United States
--------------------------------------------------------------------------------
7 SOLE VOTING POWER
NUMBER OF 0
SHARES --------------------------------------------------------------
BENEFICIALLY 8 SHARED VOTING POWER
OWNED BY 2,905,331
EACH REPORTING --------------------------------------------------------------
PERSON 9 SOLE DISPOSITIVE POWER
WITH 0
--------------------------------------------------------------
10 SHARED DISPOSITIVE POWER
2,905,331
--------------------------------------------------------------------------------
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
2,905,331
--------------------------------------------------------------------------------
12 CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES [ ]
--------------------------------------------------------------------------------
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
18.5%
--------------------------------------------------------------------------------
14 TYPE OF REPORTING PERSON
IN
--------------------------------------------------------------------------------
CUSIP NO. 98389F309 13D PAGE 17 OF 29 PAGES
Item 1. Security and Issuer
This Statement on Schedule 13D relates to the Common Stock, par value
$0.001 per share ("Common Stock"), of Xcyte Therapeutics, Inc., a corporation
incorporated under the laws of the State of Delaware ("Xcyte" or the "Issuer").
The principal executive offices of the Issuer are located at 1124 Columbia
Street, Suite 130, Seattle, Washington 98104.
Item 2. Identity and Background
(a) This Statement is being filed by (1) ARCH Venture Fund V, L.P. ("ARCH
Venture Fund V"); (2) ARCH Venture Fund III, L.P. ("ARCH Venture Fund III"), (3)
ARCH Venture Fund II, L.P. ("ARCH Venture Fund II"), (4) ARCH V Entrepreneurs
Fund, L.P. ("ARCH V Entrepreneurs Fund"), (5) Healthcare Focus Fund, L.P.
("Healthcare Focus Fund"), (6) ARCH Venture Partners V, L.P. ("AVP V LP"), which
is the sole general partner of ARCH Venture Fund V, ARCH V Entrepreneurs Fund
and Healthcare Focus Fund, (7) ARCH Venture Partners V, LLC ("AVP V LLC"), which
is the sole general partner of AVP V LP, (8) ARCH Venture Partners, LLC ("AVP
LLC"), which is the sole general partner of ARCH Venture Fund III, (9) ARCH
Management Partners II, L.P. ("ARCH Management II LP"), which is the sole
general partner of ARCH Venture Fund II, (10) ARCH Venture Partners, L.P ("AVP
LP"), which is the sole general partner of ARCH Management II LP, (11) ARCH
Venture Corporation ("AVC"), which is the sole general partner of AVP LP, (12)
Steven Lazarus ("Lazarus"), (13) Keith Crandell ("Crandell"), (14) Robert Nelsen
("Nelsen"), and (15) Clinton Bybee ("Bybee" together with Crandell, Nelsen and
Bybee, the "Managing Directors ," and each individually, a "Managing Director").
Each of the Managing Directors are individual general partners, managing
directors, directors or officers of AVP V LP, AVP V LLC, AVP LLC, ARCH
Management II LP, AVP LP and AVC, as the case may be. Each of the individuals
and entities above shall be referred to as a "Reporting Person" and
collectively, the "Reporting Persons".
(b) The residence or business address of each of the Reporting Persons is 8725
W. Higgins Road Suite 290 Chicago, IL 60631.
(c) The principal business of each of ARCH Venture Fund V, ARCH Venture Fund
III, ARCH Venture Fund II, ARCH V Entrepreneurs Fund and Healthcare Focus Fund
is to make investments. The principal business of each of AVP V LP, AVP V LLC,
AVP LLC, ARCH Management II LP, AVP LP and AVC is to act as general partner of
ARCH Venture Fund V, ARCH Venture Fund III, ARCH Venture Fund II, ARCH V
Entrepreneurs Fund and Healthcare Focus Fund, as set forth in Item 2(a). The
principal business of each of Lazarus, Crandell, Bybee and Nelsen is his
activities on behalf of the above-listed and related entities.
(d)(e) During the last five years, none of the Reporting Persons have been
convicted in a criminal proceeding (excluding traffic violations or similar
misdemeanors) or been a party to a civil proceeding of a judicial or
administrative body of competent jurisdiction and as a result of such proceeding
was or is subject to a judgment, decree or final order enjoining future
violations of, or prohibiting or mandating activities subject to, federal or
state securities laws or finding any violation with respect to such laws.
(f) Each of ARCH Venture Fund V, ARCH Venture Fund III, ARCH Venture Fund II,
ARCH V Entrepreneurs Fund, Healthcare Focus Fund, AVP V LP, ARCH Management II
LP and AVP LP are Delaware limited partnerships. AVP V LLC and AVP LLC are each
Delaware limited liability companies. AVC is an Illinois Corporation. Each of
Lazarus, Crandell, Bybee and Nelsen are United States citizens.
Item 3. Source and Amount of Funds or Other Consideration
ARCH Venture Fund II purchased 631,579 shares of the Issuer's Series A
Preferred Stock, $0.001 par value per share (the "Series A Preferred Stock"),
for an aggregate purchase price of $600,000, in a private transaction on or
about August 28, 1996. ARCH Venture Fund III purchased 157,890 shares of Series
A Preferred Stock for a purchase
CUSIP NO. 98389F309 13D PAGE 18 OF 29 PAGES
price of $150,000 in a private transaction on or about August 27, 1997. On the
same date as the foregoing purchase, ARCH Venture Fund III also acquired a
warrant to purchase 276,307 shares of Series A Preferred Stock with an exercise
price of $0.95 per share (the "ARCH III Series A Warrant"). On August 29, 1997,
ARCH Venture Fund II and ARCH Venture Fund III purchased 363,636 shares and
1,681,818 shares of the Issuer's Series B Preferred Stock, $0.001 par value per
share (the "Series B Preferred Stock"), respectively, in a private transaction
for an aggregate purchase price of $2,250,000. On July 21, 1998, ARCH Venture
Fund III purchased 1,119,265 shares of the Issuer's Series C Preferred Stock,
$0.001 par value per share (the "Series C Preferred Stock"), in a private
transaction for a purchase price of $1,869,173. On May 25, 2000, ARCH Venture
Fund III purchased 962,230 shares of the Issuer's Series D Preferred Stock,
$0.001 par value per share (the "Series D Preferred Stock"), in a private
transaction for a purchase price of $2,674,999. On August 8, 2000, ARCH Venture
Fund III purchased 359,712 shares of the Issuer's Series D Preferred Stock in a
private transaction for a purchase price of $999,999. On the same date as the
foregoing transaction, ARCH Venture Fund III acquired a warrant to purchase
40,287 shares of Common Stock for a purchase price of $40 (the "First ARCH III
Common Warrant") and, on the same date, acquired an additional warrant to
purchase 107,769 shares of Common Stock for a purchase price of $108 (the
"Second ARCH III Common Warrant"). The exercise price for each of the First ARCH
III Common Warrant and Second ARCH III Common Warrant was $0.30 per share. On
November 13, 2001, ARCH Venture Fund III purchased 935,251 shares of the
Issuer's Series E Preferred Stock, $0.001 par value per share (the "Series E
Preferred Stock") in a private transaction for a purchase price of $2,599,998.
On the same date as the foregoing transaction, ARCH Venture Fund III acquired a
warrant to purchase 509,192 shares of Common Stock for $0.01 per share (the
"Third ARCH III Common Warrant"). On February 5, 2002, the Healthcare Focus Fund
purchased 899,104 shares of the Issuer's Series F Preferred Stock, $.001 par
value per share ("the Series F Preferred Stock", collectively with the Series A
Preferred Stock, the Series B Preferred Stock, the Series C Preferred Stock, the
Series D Preferred Stock and the Series E Preferred Stock, the "Series Preferred
Stock"), for $2,499,509. On the same date as the foregoing transaction,
Healthcare Focus Fund acquired a warrant to purchase 489,512 shares of Common
Stock for $0.01 per share (the "Healthcare Focus Fund Warrant").
On October 8, 2003, ARCH Venture Fund III, ARCH Venture Fund V, ARCH V
Entrepreneurs Fund and Healthcare Focus Fund were issued promissory notes by the
Issuer in the principal amounts of $575,000, $1,986,614, $13,386 and $750,000,
respectively. Pursuant to the terms of each note, the principal and interest
would convert to shares of Common Stock at a price per share of $9.625 at the
time of the Issuer's initial public offering (the "IPO").
Pursuant to their respective terms, each share of Series Preferred Stock
automatically converts into shares of Common Stock upon the effective date of
the Issuer's IPO. On March 19, 2004, the Issuer effected a
one-for-five-and-one-half reverse stock split of its Common Stock and, as a
result, each of the shares of Series Preferred Stock was convertible into
approximately one-sixth of a share of Common Stock.
Each of the ARCH III Series A Warrant, the First ARCH III Common Warrant,
the Second ARCH III Common Warrant, the Third ARCH III Common Warrant and the
Healthcare Focus Fund Warrant converted upon the Issuer's IPO into 17,425
shares, 5,813 shares, 15,552 shares, 91,943 shares, and 88,390 shares,
respectively, of Common Stock pursuant to the cashless exercise provisions of
each such warrant.
On March 19, 2004, ARCH Venture Fund II, ARCH Venture Fund V and
Healthcare Focus Fund purchased an additional 12,500 shares (for a purchase
price of $100,000), 137,500 shares (for a purchase price of $1,100,000) and
37,500 shares (for a purchase price of $300,000), respectively, of Common Stock
in connection with the Issuer's IPO.
On November 3, 2004, ARCH Venture Fund V and ARCH V Entrepreneurs Fund
purchased 198,661 shares and 1,339 shares, respectively, of the Issuer's 6%
Convertible Exchangeable Preferred Stock (the "Convertible Exchangeable
Preferred Stock") in conjunction with a offering by the Issuer for a purchase
price of $10 per share. The shares of Convertible Exchangeable Preferred Stock
are convertible into shares of Common Stock at initial conversion price of
$2.35, subject to certain adjustments.
The working capital of each of the above-listed purchasing entities was
the source of the funds for each purchase. No part of the purchase price paid by
these entities was represented by funds or other consideration
CUSIP NO. 98389F309 13D PAGE 19 OF 29 PAGES
borrowed or otherwise obtained for the purpose of acquiring, holding, trading or
voting the shares of Common Stock, Series Preferred Stock and Convertible
Exchangeable Preferred Stock described above.
Item 4. Purpose of Transaction
Each of ARCH Venture Fund V, ARCH Venture Fund III, ARCH Venture Fund II,
ARCH V Entrepreneurs Fund and Healthcare Focus Fund acquired the Common Stock
for investment purposes. Depending on market conditions, the continuing
evaluation of the business and prospects of the Issuer and other factors, each
of ARCH Venture Fund V, ARCH Venture Fund III, ARCH Venture Fund II, ARCH V
Entrepreneurs Fund and Healthcare Focus Fund and other Reporting Persons may
dispose of or acquire additional shares of Common Stock of the Issuer. Nelsen is
a member of the Board of Directors. Except as set forth above, none of the
Reporting Persons has any present plans which relate to or would result in:
(a) The acquisition by any person of additional securities of the
Issuer, or the disposition of securities of the Issuer;
(b) An extraordinary corporate transaction, such as a merger,
reorganization or liquidation, involving the Issuer or any of its
subsidiaries;
(c) A sale or transfer of a material amount of assets of the Issuer or
any of its subsidiaries;
(d) Any change in the present board of directors or management of the
Issuer, including any plans or proposals to change the number or
term of directors or to fill any existing vacancies on the board;
(e) Any material change in the present capitalization or dividend policy
of the Issuer;
(f) Any other material change in the Issuer's business or corporate
structure;
(g) Changes in the Issuer's charter, bylaws or instruments corresponding
thereto or other actions which may impede the acquisition of control
of the Issuer by any person;
(h) Causing a class of securities of the Issuer to be delisted from a
national securities exchange or to cease to be authorized to be
quoted in an inter-dealer quotation system of a registered national
securities association;
(i) A class of equity securities of the Issuer becoming eligible for
termination of registration pursuant to Section 12(g)(4) of the
Securities Exchange Act of 1934; or
(j) Any action similar to any of those enumerated above.
Item 5. Interest in Securities of the Issuer.
(a) As of the date of this Schedule and assuming conversion of the
Convertible Exchangeable Preferred Stock at the initial conversion price of
$2.35 as reported by the Issuer in Issuer's 424B3 Prospectus filed on November
1, 2004, ARCH Venture Fund V is the record holder of 1,194,870 shares of Common
Stock, ARCH Venture Fund III is the record holder of 1,140,487 shares of Common
Stock, ARCH Venture Fund II is the record holder of 193,447 shares of Common
Stock, ARCH V Entrepreneurs Fund is the record holder of 7,126 shares of Common
Stock and Healthcare Focus Fund is the record holder of 369,401 shares of Common
Stock (the aggregate of such shares of Common Stock shall be referred to as the
"ARCH Shares"). By virtue of their relationship as affiliated entities, whose
general partners have overlapping individual general partners, managing members,
directors and officers, as the case may be, each Reporting Person may be deemed
to own beneficially all of the ARCH Shares. The Reporting Persons expressly
disclaim membership in a "group" as used in Rule 13d-1(b)(ii)(H). Each Reporting
Person also expressly
CUSIP NO. 98389F309 13D PAGE 20 OF 29 PAGES
disclaims beneficial ownership of any shares of Common Stock of the Issuer,
except for the shares, if any, such Reporting Person holds of record.
The shares of Common Stock held by the Reporting Persons represent
approximately 18.5% of the Common Stock outstanding, based upon 14,826,573
shares of Common Stock reported by the Issuer to be outstanding in the Issuer's
424B3 Prospectus filed on November 1, 2004 and assuming conversion of the shares
of Convertible Exchangeable Preferred Stock held of record by ARCH Venture Fund
V and ARCH V Entrepreneurs Fund into 845,362 and 5,698 shares of Common Stock,
respectively, based on the initial conversion price of $2.35 as reported by the
Issuer in Issuer's 424B3 Prospectus filed on November 1, 2004.
(b) Number of shares of Common Stock as to which each such Reporting
Person has:
(i) sole power to vote or to direct the vote:
0 shares
(ii) shared power to vote or to direct the vote:
2,905,331 shares for each Reporting Person.
(iii) sole power to dispose or to direct the disposition:
0 shares
(iv) shared power to dispose or to direct the disposition:
2,905,331 shares for each Reporting Person.
(c) On November 3, 2004, the Issuer completed a sale of shares of its
Convertible Exchangeable Preferred Stock to ARCH Venture Fund V, ARCH V
Entrepreneurs Fund and other investors. The shares of Convertible Exchangeable
Preferred Stock purchased by ARCH Venture Fund V and ARCH V Entrepreneurs Fund
are convertible into 845,362 and 5,698 shares of Common Stock, respectively,
based on the initial conversion price of $2.35 as reported by the Issuer in
Issuer's 424B3 Prospectus filed on November 1, 2004.
(d) Not applicable.
(e) Not applicable.
Item 6. Contracts, Arrangements, Understandings or Relationships with Respect
to Securities of the Issuer
Except for the transactions described in this Schedule, none of the
Reporting Persons have any contract, arrangement, understanding or relationship
(legal or otherwise) with any other person with respect to any securities of the
Issuer, including but not limited to transfer or voting of any such securities,
finder's fees, joint ventures, loan or option arrangements, puts or calls,
guarantees of profits, division of profits or loss or the giving or withholding
of proxies.
Item 7. Material to be filed as Exhibits
Exhibit 1. Agreement of Joint Filing
Exhibit 2. Power of Attorney
CUSIP NO. 98389F309 13D PAGE 21 OF 29 PAGES
SIGNATURE
After reasonable inquiry and to the best of its knowledge and belief, each
of the undersigned certifies that the information set forth in this Statement is
true, complete and correct. We also hereby agree to file this statement jointly
pursuant to the Agreement listed on Exhibit 1 hereto.
Date: November 12, 2004
ARCH VENTURE FUND V, L.P.
By: ARCH Venture Partners V, L.P.
its General Partner
By: ARCH Venture Partners V, LLC
Its General Partner
By: *
----------------------------
Managing Director
ARCH VENTURE FUND III, L.P.
By: ARCH Venture Partners, LLC
its General Partner
By: *
---------------------------
Managing Director
ARCH VENTURE FUND II, L.P.
By: ARCH Management Partners II, L.P.
Its General Partner
By: ARCH Venture Partners, L.P.
Its General Partner
By: ARCH Venture Corporation
Its General Partner
By: *
--------------------------------
Managing Director
CUSIP NO. 98389F309 13D PAGE 22 OF 29 PAGES
ARCH V ENTREPRENEURS FUND V, L.P.
By: ARCH Venture Partners V, L.P.
its General Partner
By: ARCH Venture Partners V, LLC
Its General Partner
By: *
---------------------------
Managing Director
HEALTHCARE FOCUS FUND, L.P.
By: ARCH Venture Partners V, L.P.
its General Partner
By: ARCH Venture Partners V, LLC
Its General Partner
By: *
---------------------------
Managing Director
ARCH VENTURE PARTNERS V, L.P.
By: ARCH Venture Partners V, LLC
Its General Partner
By: *
----------------------------
Managing Director
ARCH VENTURE PARTNERS V, LLC
By: *
----------------------------------------
Managing Director
ARCH VENTURE PARTNERS, LLC
By: *
----------------------------------------
Managing Director
CUSIP NO. 98389F309 13D PAGE 23 OF 29 PAGES
ARCH MANAGEMENT PARTNERS II, L.P.
By: ARCH Venture Partners, L.P.
its General Partner
By: ARCH Venture Corporation
its General Partner
By: *
---------------------------------
Managing Director
ARCH VENTURE PARTNERS, L.P.
By: ARCH Venture Corporation
its General Partner
By: *
---------------------------
Managing Director
ARCH VENTURE CORPORATION
By: *
----------------------------------------
Managing Director
*
-----------------------------------
Steven Lazarus
*
-----------------------------------
Keith Crandell
*
-----------------------------------
Robert Nelsen
*
-----------------------------------
Clinton Bybee
* By: /s/ Mark McDonnell
Mark McDonnell as
Attorney-in-Fact
CUSIP NO. 98389F309 13D PAGE 24 OF 29 PAGES
Exhibit 1
AGREEMENT OF JOINT FILING
Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934,
the undersigned hereby agree that only one statement containing the information
required by Schedule 13D need be filed with respect to the ownership by each of
the undersigned of shares of Common Stock of Xcyte Therapies, Inc.
EXECUTED this 12th day of November, 2004.
ARCH VENTURE FUND V, L.P.
By: ARCH Venture Partners V, L.P.
its General Partner
By: ARCH Venture Partners V, LLC
Its General Partner
By: *
---------------------------
Managing Director
ARCH VENTURE FUND III, L.P.
By: ARCH Venture Partners, LLC
its General Partner
By: *
--------------------------
Managing Director
ARCH VENTURE FUND II, L.P.
By: ARCH Management Partners II, L.P.
Its General Partner
By: ARCH Venture Partners, L.P.
Its General Partner
By: ARCH Venture Corporation
Its General Partner
By: *
--------------------------------
Managing Director
CUSIP NO. 98389F309 13D PAGE 25 OF 29 PAGES
ARCH V ENTREPRENEURS FUND V, L.P.
By: ARCH Venture Partners V, L.P.
its General Partner
By: ARCH Venture Partners V, LLC
Its General Partner
By: *
--------------------------
Managing Director
HEALTHCARE FOCUS FUND, L.P.
By: ARCH Venture Partners V, L.P.
its General Partner
By: ARCH Venture Partners V, LLC
Its General Partner
By: *
--------------------------
Managing Director
ARCH VENTURE PARTNERS V, L.P.
By: ARCH Venture Partners V, LLC
Its General Partner
By: *
---------------------------
Managing Director
ARCH VENTURE PARTNERS V, LLC
By: *
----------------------------------------
Managing Director
ARCH VENTURE PARTNERS, LLC
By: *
----------------------------------------
Managing Director
CUSIP NO. 98389F309 13D PAGE 26 OF 29 PAGES
ARCH MANAGEMENT PARTNERS II, L.P.
By: ARCH Venture Partners, L.P.
its General Partner
By: ARCH Venture Corporation
its General Partner
By: *
--------------------------------
Managing Director
ARCH VENTURE PARTNERS, L.P.
By: ARCH Venture Corporation
its General Partner
By: *
--------------------------
Managing Director
ARCH VENTURE CORPORATION
By: *
----------------------------------------
Managing Director
*
-----------------------------------
Steven Lazarus
*
-----------------------------------
Keith Crandell
*
-----------------------------------
Robert Nelsen
*
-----------------------------------
Clinton Bybee
* By: /s/ Mark McDonnell
Mark McDonnell as
Attorney-in-Fact
CUSIP NO. 98389F309 13D PAGE 27 OF 29 PAGES
Exhibit 2
POWERS OF ATTORNEY
KNOW ALL MEN BY THESE PRESENTS, that each person whose signature appears
below hereby constitutes and appoints Mark McDonnell his true and lawful
attorney-in-fact, with full power of substitution, to sign any and all
instruments, certificates and documents that may be necessary, desirable or
appropriate to be executed on behalf of himself as an individual or in his
capacity as a general partner of any partnership, pursuant to Sections 13 and 16
of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and any
and all regulations promulgated thereunder, and to file the same, with all
exhibits thereto, and any other documents in connection therewith, with the
Securities and Exchange Commission, and with any other entity when and if such
is mandated by the Exchange Act or by the By-laws of the National Association of
Securities Dealers, Inc., granting unto said attorney-in-fact full power and
authority to do and perform each and every act and thing necessary, desirable or
appropriate, fully to all intents and purposes as he might or could do in
person, thereby ratifying and confirming all that said attorney-in-fact, or his
substitutes, may lawfully do or cause to be done by virtue hereof.
ARCH VENTURE FUND V, L.P.
By: ARCH VENTURE PARTNERS V, L.P.
its General Partner
By: ARCH Venture Partners V, LLC
Its General Partner
By: /s/ Keith Crandell
---------------------------
Managing Director
ARCH VENTURE FUND iii, L.P.
By: ARCH Venture Partners, LLC
its General Partner
By: /s/ Keith Crandell
--------------------------
Managing Director
ARCH VENTURE FUND II, L.P.
By: ARCH Management Partners II, L.P.
Its General Partner
By: ARCH Venture Partners, L.P.
Its General Partner
By: ARCH Venture Corporation
Its General Partner
By: /s/ Keith Crandell
--------------------------------
Managing Director
CUSIP NO. 98389F309 13D PAGE 28 OF 29 PAGES
ARCH v ENTREPRENEURS FUND V, L.P.
By: ARCH Venture Partners V, L.P.
its General Partner
By: ARCH Venture Partners V, LLC
Its General Partner
By: /s/ Keith Crandell
--------------------------
Managing Director
HEALTHCARE FOCUS FUND, L.P.
By: ARCH Venture Partners V, L.P.
its General Partner
By: ARCH Venture Partners V, LLC
Its General Partner
By: /s/ Keith Crandell
--------------------------
Managing Director
ARCH VENTURE PARTNERS V, L.P.
By: ARCH Venture Partners V, LLC
Its General Partner
By: /s/ Keith Crandell
---------------------------
Managing Director
ARCH VENTURE PARTNERS V, LLC
By: /s/ Keith Crandell
-------------------------------
Managing Director
ARCH VENTURE PARTNERS, LLC
By: /s/ Keith Crandell
-------------------------------
Managing Director
CUSIP NO. 98389F309 13D PAGE 29 OF 29 PAGES
ARCH MANAGEMENT PARTNERS II, L.P.
By: ARCH Venture Partners, L.P.
its General Partner
By: ARCH Venture Corporation
its General Partner
By: /s/ Keith Crandell
--------------------------------
Managing Director
ARCH VENTURE PARTNERS, L.P.
By: ARCH Venture Corporation
its General Partner
By: /s/ Keith Crandell
--------------------------
Managing Director
ARCH VENTURE CORPORATION
By: /s/ Keith Crandell
-------------------------------
Managing Director
/s/ Steven Lazarus
-----------------------------------
Steven Lazarus
/s/ Keith Crandell
-----------------------------------
Keith Crandell
/s/ Robert Nelsen
---------------------------
Robert Nelsen
/s/ Clinton Bybee
---------------------------
Clinton Bybee